Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | CKS1B | P61024 | 2/20 | 0.46 |
| ▸ | SKP1 | P63208 | 2/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22944628 | 0.97 | NAMPT (0.48) | MAPK1PDK4NAMPTGPR119ESR2 | |
| SCHEMBL22945388 | 0.91 | USP30 (0.48) | MAPK1PDK4GPR119ESR2RORC | |
| SCHEMBL22944329 | 0.90 | TNK2 (0.49) | MAPK1PDK4NAMPTGPR119ESR2 | |
| SCHEMBL29197658 | 0.88 | ESR2 (0.55) | MAPK1PDK4NAMPTGPR119ESR2 | |
| SCHEMBL21425203 | 0.87 | MAPK1 (0.41) | MAPK1PDK4GPR119ESR2RORC | |
| SCHEMBL28835616 | 0.86 | NR1H2 (0.56) | MAPK1PDK4NAMPTGPR119ESR2 | |
| SCHEMBL22441484 | 0.86 | GRM1 (0.48) | MAPK1PDK4NAMPTGPR119ESR2 | |
| SCHEMBL22945237 | 0.86 | MEN1 (0.51) | MAPK1PDK4NAMPTESR2NR1H2 | |
| SCHEMBL19459096 | 0.86 | ESR2 (0.45) | MAPK1PDK4NAMPTESR2RORC | |
| SCHEMBL14262836 | 0.86 | PDK4 (0.56) | MAPK1PDK4NAMPTGPR119CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073856-B2 | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140371269-A1 | PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2014-12-18 | — | — | US | disclosed |
| EP-2807147-A1 | PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT - 2 INHIBITORS | Eli Lilly and Company (US) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013112323-A1 | PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT - 2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2013-08-01 | — | — | WO | disclosed |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | MAPK1 1886/4885PDK4 824/4885NAMPT 2899/4885 |
| US-20140371269-A1 | PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT-2 INHIBITORS | MGST1, MGAT1, MGAT2 | MAPK1 1387/4885PDK4 1069/4885NAMPT 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.